Pomalidomide-Containing Regimens (PCR) for the Treatment of Relapsed and Refractory Multiple Myeloma

被引：0
|
作者：
Jimenez-Zepeda, Victor H. [1 ]
Venner, Christopher P. [2 ]
Belch, Andrew [3 ]
Sandhu, Irwindeep [4 ]
Nikitina, Tatiana [2 ]
Hewitt, Joanne D. [5 ]
Duggan, Peter [6 ]
Neri, Paola [7 ]
Rashid-Kolvear, Fariborz [8 ]
Bahlis, Nizar J. [7 ]
机构：
[1] Univ Calgary, Div Hematol, Calgary, AB, Canada
[2] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Univ Alberta, Dept Med, Div Hematol, Edmonton, AB, Canada
[5] Cross Canc Inst, Nursing, Edmonton, AB T6G 1Z2, Canada
[6] Tom Baker Canc Clin, Dept Med Oncol & Hematol, Calgary, AB, Canada
[7] Univ Calgary, Southern Alberta Canc Res Inst, Calgary, AB, Canada
[8] Calgary Lab Serv, Calgary, AB, Canada
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison
    Weisel, Katja
    Dimopoulos, Meletios A.
    Beksac, Meral
    Leleu, Xavier
    Richter, Joshua
    Heeg, Bart
    Patel, Sachin
    Majer, Istvan
    McFadden, Ian
    Mikhael, Joseph
    LEUKEMIA & LYMPHOMA, 2024, 65 (04) : 481 - 492
  • [2] Pomalidomide for the treatment of relapsed and refractory multiple myeloma
    Guidetti, Anna
    Prada, Claudia Paba
    Laubach, Jacob P.
    Varga, Cindy
    Maglio, Michelle E.
    McKenney, Mary
    Doss, Deborah
    Schlossman, Robert L.
    Mitsiades, Constantine
    Hideshima, Teru
    Gorgun, Gullu T.
    Ghobrial, Irene M.
    Raje, Noopur
    Munshi, Nikhil
    Anderson, Kenneth C.
    Richardson, Paul G.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (10): : 1089 - 1108
  • [3] Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
    Fotiou, Despina
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [4] Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma
    Hoy, Sheridan M.
    DRUGS, 2017, 77 (17) : 1897 - 1908
  • [5] Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma
    Sheridan M. Hoy
    Drugs, 2017, 77 : 1897 - 1908
  • [6] Pomalidomide in the treatment of relapsed multiple myeloma
    Forsberg, Peter A.
    Mark, Tomer M.
    FUTURE ONCOLOGY, 2013, 9 (07) : 939 - 948
  • [7] Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma
    Palumbo, Antonio
    Larocca, Alessandra
    Montefusco, Vittorio
    Rossi, Davide
    Carella, Angelo Michele
    Mina, Roberto
    Crippa, Claudia
    Sciacca, Mariella
    Galli, Monica
    Scalabrini, Delia Rota
    Marcatti, Magda
    Guglielmelli, Tommasina
    Giuliani, Nicola
    La Verde, Giacinto
    Baldi, Ileana
    Muccio, Vittorio Emanuele
    Boccadoro, Mario
    Corradini, Paolo
    BLOOD, 2012, 120 (21)
  • [8] Pomalidomide: A novel imunomodulatory drug for the treatment of relapsed and refractory multiple myeloma
    Bajaj, Nikki
    Shaaban, Hamid
    Maroules, Michael
    Guron, Gunwant
    CLINICAL CANCER INVESTIGATION JOURNAL, 2014, 3 (03): : 200 - 207
  • [9] Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma
    Mark, Tomer M.
    Coleman, Morton
    Niesvizky, Ruben
    LEUKEMIA RESEARCH, 2014, 38 (05) : 517 - 524
  • [10] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Dharshan Sivaraj
    Michael M Green
    Yubin Kang
    Gwynn D Long
    David A Rizzieri
    Zhiguo Li
    Anderson H Garrett
    Jackie L McIntyre
    Nelson J Chao
    Cristina Gasparetto
    Blood Cancer Journal, 8
12345